Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 02 - 18 tags : Program save search
Material Fact: Pause in the E175-E2 Jet Development Program
Published: 2022-02-18 (Crawled : 00:20) - prnewswire.com
ERJ | $24.28 0.33% 0.25% 1.6M
|
Electronic Technology
| Email alert
Add to watchlist
program
Data from Codiak’s exoASO™-STAT6 Preclinical Development Program for the Treatment of Primary and Metastatic Hepatic Cancers Published in Science Advances
Published: 2022-02-18 (Crawled : 19:00) - globenewswire.com
CDAK | $0.057 -55.99% -131.25% 0
|
Health Technology
| Email alert
Add to watchlist
treatment program preclinical cancer pre-clinical
Moderna Expands Its mRNA Pipeline with Three New Development Programs
Published: 2022-02-18 (Crawled : 13:30) - biospace.com/
MRNA | News S | $107.89 3.28% 3.16% 2M
|
Health Technology
|
| O: 0.81%
H: 2.65%
C: -1.23%
program
Reata Pharmaceuticals, Inc. To Report Fourth Quarter and Full Year 2021 Financial Results and To Provide an Update on Development Programs on February 28, 2022
Published: 2022-02-18 (Crawled : 12:30) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.99%
H: 3.66%
C: -0.69%
als financial results program report results
Global Space-qualified Propellant Tank Market Opportunities to 2031: Growing Developments for Deep Space Exploration Programs
Published: 2022-02-18 (Crawled : 11:00) - prnewswire.com
NOC | $474.68 0.79% 0.0% 1.2M
|
Electronic Technology
|
| O: -0.15%
H: 0.5%
C: -1.57%
LMT | $460.08 -0.27% 0.3% 1.6M
|
Electronic Technology
|
| O: 0.1%
H: 0.5%
C: -0.69%
space program propel growing spac
Coloplast A/S - Announcement no. 03/2022 - Share Buyback Programme
Published: 2022-02-18 (Crawled : 10:00) - globenewswire.com
CLPBF | $124.23 -3.83% -17.82% 0
|
Health Technology
|
| O: -8.4%
H: 2.71%
C: 1.63%
CLPBY | $13.26 2.39% -1.22% 66K
|
Manufacturing
|
| O: -1.27%
H: 0.0%
C: -0.86%
program announcement
Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program
Published: 2022-02-18 (Crawled : 09:00) - biospace.com/
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: -0.78%
H: 1.76%
C: -1.08%
dupixent ongoing program phase 3 urticaria
Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program
Published: 2022-02-18 (Crawled : 07:00) - prnewswire.com
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: -0.78%
H: 1.76%
C: -1.08%
dupixent ongoing program phase 3 urticaria
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 26M
|
AGBA | $2.97 137.6% 57.48% 66M
|
Finance
EDBL | News | $6.59 75.27% 41.8% 2M
|
ZAPP | $4.44 50.2% 33.12% 370K
|
n/a
MTC | $2.24 43.59% 30.67% 6M
|
Technology Services
OPRT | News | $3.15 40.0% 29.13% 12M
|
Finance
SHIM | $3.045 35.33% 26.23% 870K
|
HKIT | $1.33 30.39% 24.16% 390K
|
Technology Services
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
OST | $0.5 25.0% 21.88% 280K
|
Your saved searches
Save your searches and get alerts when important news are released.